Lars Jorgensen, general director of Novo Nordisk, testifies before interrogation in the Committee of the Senate Committee, Education, Work and Pensions on the prices of American drugs for slimming Ozempic and Wegova, at Capitol Hill in Washington, USA, 24 September 2024.
Piroschka van de wouw | Reuters
Novo Nordisk CEO Lars Fruergaard Jørgensen subsides, said Wegova-Maker on Friday, citing recent market challenges.
The Danish pharmaceutical giant said that Fruergaard Jørgensen would remain in his position “for a period to support a smooth transition to new leadership.” She added that the search for a replacement was in progress and the advertisement would be announced at the right time.
The shares fell by 1.8% shortly after the announcement.
The decision comes because the price of Novo Nordisk's action has come over the past year among increased competition on the market of obese balloon drugs and disappointing test results for new generation treatment.
Chairman Helge Lund said, however, that the drug manufacturer's approach is unchanged.
“Novo Nordisk strategy remains unchanged, and the management is convinced of the company's current business plans and its ability to implement plans,” Lund said in a statement.
This is a story about the most important news, check updates.